[1]吴 刚,吴锦瑜.HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义[J].医学信息,2018,31(19):96-98.[doi:10.3969/j.issn.1006-1959.2018.19.028]
　WU Gang,WU Jin-yu.Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B[J].Medical Information,2018,31(19):96-98.[doi:10.3969/j.issn.1006-1959.2018.19.028]
点击复制

HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的检测及临床意义()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年19期
页码:
96-98
栏目:
论著
出版日期:
2018-10-01

文章信息/Info

Title:
Detection and Clinical Significance of Serum 25-hydroxyvitamin D3 in Patients with HBeAg-negative Chronic Hepatitis B
文章编号:
1006-1959（2018）19-0096-03
作者:
吴 刚; 吴锦瑜
九江市第一人民医院肝病科，江西 九江 332000
Author(s):
WU Gang; WU Jin-yu
Department of Liver Diseases,Jiujiang First People’s Hospital,Jiujiang 332000,Jiangxi,China
关键词:
HBeAg阴性; 慢性乙型肝炎; 25-羟基维生素D3; HBV DNA
Keywords:
HBeAg negative; Chronic hepatitis B; 25-hydroxyvitamin D3; HBV DNA
分类号:
R512.6；R575.1
DOI:
10.3969/j.issn.1006-1959.2018.19.028
文献标志码:
A
摘要:
目的 探究HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3的水平变化及临床意义。方法 选取2015年3月~2018年5月81例HBeAg阴性且非肝硬化的慢性乙型肝炎患者作为观察组，依据血清谷丙转氨酶（ALT）水平分为观察组A 41例（ALT处于正常水平且HBV DNA水平＜2000 IU/ml，持续时间高于6个月）和观察组B 40例（ALT处于升高水平且HBV DNA水平≥2000 IU/ml，持续时间高于6个月）。同时选取同期健康体检人群40例作为对照组。分别检测三组血清25-羟基维生素D3的浓度。结果 观察组血清25-羟基维生素D3低于健康人群，统计学意义显著（P＜0.001），三组间比较，统计学意义显著（P＜0.001）。观察组患者血清25-羟基维生素D3与年龄、BMI、ALT、AST、Hb、WBC、PLT及AFP均无明显相关性（P＞0.05）。而与HBV DNA含量间存在显著负相关（r=-3.981，P＜0.05）。结论 HBeAg阴性慢性乙型肝炎患者血清25-羟基维生素D3存在异常，并与乙肝病毒复制相关，可能参与机体和乙肝病毒的免疫反应过程。
Abstract:
Objective To investigate the changes and clinical significance of serum 25-hydroxyvitamin D3 levels in patients with HBeAg-negative chronic hepatitis B.Methods From March 2015 to May 2018,81 patients with HBeAg-negative and non-cirrhotic chronic hepatitis B were enrolled as observation group.According to serum alanine aminotransferase(ALT)levels,41 patients in observation group A(ALT was at normal level and HBV DNA level was <2000 IU/ml,duration was higher than 6 months)and 40 patients in group observation B(ALT was at elevated level and HBV DNA level was ≥2000 IU/ml for more than 6 months).At the same time,40 healthy people in the same period were selected as the control group.The concentrations of serum 25-hydroxyvitamin D3 were measured separately.Results The serum 25-hydroxyvitamin D3 in the observation group was lower than that in the healthy group,and the statistical significance was significant (P<0.001).The comparison between the three groups was statistically significant(P<0.001).There was no significant correlation between serum 25-hydroxyvitamin D3 and age,BMI,ALT,AST,Hb,WBC, PLT and AFP in the observation group(P>0.05).There was a significant negative correlation with HBV DNA content(r=-3.981,P<0.05).Conclusion The serum of 25-hydroxyvitamin D3 in patients with HBeAg-negative chronic hepatitis B is abnormal and related to hepatitis B virus replication, which may be involved in the immune response process between the body and hepatitis B virus.

参考文献/References:

[1]孟庆华,侯维.2015年版《慢性乙型肝炎防治指南》——慢性乙型肝炎抗病毒治疗指南解读[J].中国全科医学,2016,19(14):1613-1615. [2]赵明远,武希润.维生素D介导的免疫调节在肝纤维化中的作用机制[J].中国药物与临床,2017,17(6):837-840. [3]An P,Ling L,Franco OH,et al.Association between depressive symptoms and 25-hydroxyvitamin D in middle-aged and elderly Chinese[J].J Affect Disord,2009,118(1-3):240-243. [4]夏向群,胡爱荣,蒋素文,等.核苷和核苷酸类药物在慢性乙型肝炎病毒感染者中的应用及耐药突变分析[J].中国现代应用药学,2016,33(6):810-814. [5]Dao C N,Patel P,Overton E T,et al.Low Vitamin D among HIV-Infected Adults: Prevalence of and Risk Factors for Low Vitamin D Levels in a Cohort of HIV-Infected Adults and Comparison to Prevalence among Adults in the US General Population[J].Clinical Infectious Diseases,2011, 52(3):396-405. [6]欧阳福,谭萃,王君宜,等.维生素D与肝硬化的研究进展[J].实用医学杂志,2017,33(15):2453-2456. [7]Hoan NX,Khuyen N,Binh MT,et al.Association of vitamin D deficiency with hepatitis B virus -related liver diseases[J].Bmc Infectious Diseases,2016,16(1):507.

相似文献/References:

[1]林晓岚,郑丽花,陈苑莉,等.微信随访对慢性乙型肝炎患者抗病毒治疗效果和 生活质量的影响研究[J].医学信息,2018,31(10):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
　LIN Xiao-lan,ZHENG Li-hua,CHEN Yuan-li,et al.Effect of WeChat Follow-up on Antiviral Treatment and Quality of Life in Patients with Chronic Hepatitis B[J].Medical Information,2018,31(19):164.[doi:10.3969/j.issn.1006-1959.2018.10.057]
[2]林晓岚,陈苑莉.慢性乙型肝炎患者治疗依从性及其对生活质量的影响[J].医学信息,2018,31(13):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
　LIN Xiao-lan,CHEN Yuan-li.Treatment Compliance of Patients with Chronic Hepatitis B and its Influence on Quality of Life[J].Medical Information,2018,31(19):168.[doi:10.3969/j.issn.1006-1959.2018.13.052]
[3]陈 欢,李秀惠.急、慢性乙型肝炎及乙肝肝硬化患者 肝功能及血脂水平分析[J].医学信息,2019,32(12):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
　CHEN Huan,LI Xiu-hui.Analysis of Liver Function and Blood Lipid Levels in Patients with Acute, Chronic Hepatitis B and Hepatitis B Cirrhosis[J].Medical Information,2019,32(19):67.[doi:10.3969/j.issn.1006-1959.2019.12.021]
[4]叶向荣.恩替卡韦治疗慢性乙型肝炎病毒感染的临床价值评价[J].医学信息,2018,31(22):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
　YE Xiang-rong.Clinical Evaluation of Entecavir in Treatment of Patients with Chronic Hepatitis B Virus Infection[J].Medical Information,2018,31(19):147.[doi:10.3969/j.issn.1006-1959.2018.22.043]
[5]汪晓凤,邵和军.慢性乙型肝炎抗病毒治疗进展[J].医学信息,2019,32(04):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
　WANG Xiao-feng,SHAO He-jun.Progress in Antiviral Therapy for Chronic Hepatitis B[J].Medical Information,2019,32(19):39.[doi:10.3969/j.issn.1006-1959.2019.04.015]
[6]傅 蕊,李士欣,周国强,等.床旁超声预测慢性乙型肝炎患者胃镜检查围麻醉期误吸风险的临床价值[J].医学信息,2019,32(08):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
　FU Rui,LI Shi-xin,ZHOU Guo-qiang,et al.Clinical Value of Bedside Ultrasound in Predicting the Risk of Aspiration during Perioperative Anesthesia in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(19):123.[doi:10.3969/j.issn.1006-1959.2019.08.035]
[7]张媛媛,徐 曼.慢性乙型肝炎患者e抗原消失的临床特点[J].医学信息,2019,32(10):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
　ZHANG Yuan-yuan,XU Man.Clinical Features of e Antigen Disappearance in Patients with Chronic Hepatitis B[J].Medical Information,2019,32(19):105.[doi:10.3969/j.issn.1006-1959.2019.10.033]
[8]罗 丹,梁惠卿,吴耀南.吴耀南教授基于“伏邪”理论治疗慢性乙肝的验案举隅[J].医学信息,2019,32(19):158.[doi:10.3969/j.issn.1006-1959.2019.19.052]
[9]周腾腾,郑 莹,梁恵卿,等.蛋白质组学在慢性乙型肝炎常见中医证型中的研究[J].医学信息,2019,32(20):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
　ZHOU Teng-teng,ZHENG Ying,LIANG Hui-qing,et al.Study on Proteomics in Common TCM Syndromes of Chronic Hepatitis B[J].Medical Information,2019,32(19):30.[doi:10.3969/j.issn.1006-1959.2019.20.009]
[10]王佳欣,毛乾国.慢性乙型肝炎合并非酒精性脂肪性肝病 中医辨治的研究进展[J].医学信息,2019,32(16):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]
　WANG Jia-xin,MAO Qian-guo.Advances in Research on TCM Syndrome Differentiation of Chronic Hepatitis B with Nonalcoholic Fatty Liver Disease[J].Medical Information,2019,32(19):38.[doi:10.3969/j.issn.1006-1959.2019.16.012]

更新日期/Last Update: 2018-10-29